Develops treatments for retinal diseases and metabolic disorders, aiming to address significant unmet medical needs.
Belite Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing novel therapeutics for debilitating ocular and liver diseases. Founded in 2016 and headquartered in San Diego, California, Belite Bio focuses on pioneering treatments for conditions such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease. At the forefront of its pipeline is LBS-008, an innovative oral therapy currently in phase 3 clinical trials. This once-a-day treatment aims to regulate and sustain the delivery of vitamin A to the eye, thereby mitigating the accumulation of harmful by-products in ocular tissues.
In addition to its work in ophthalmology, Belite Bio is actively developing LBS-009, an oral therapy targeting liver diseases including non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and type 2 diabetes. LBS-009 specifically targets retinol binding protein 4 (RBP4), a key player in metabolic and liver-related disorders, and is currently in preclinical development. By leveraging its expertise in biotherapeutics, Belite Bio seeks to address significant unmet medical needs through innovative approaches that improve patient outcomes and quality of life.
As a subsidiaary of Lin Bioscience International Ltd., Belite Bio benefits from a strong foundation in biopharmaceutical research and development. With a commitment to rigorous scientific inquiry and patient-centric innovation, the company aims to establish itself as a leader in the field of precision medicine, driving forward transformative treatments that redefine standards of care across multiple therapeutic areas.